# A Phase 2a, Proof-of-Concept Study of GIC-1001 in the Management of Visceral Pain During Sedation-Free, Full Colonoscopy

> **NCT01926444** · PHASE2 · COMPLETED · sponsor: **gicare Pharma Inc.** · enrollment: 308 (actual)

## Conditions studied

- Pain
- Cancer
- Colonic Diseases

## Interventions

- **DRUG:** GIC-1001

## Key facts

- **NCT ID:** NCT01926444
- **Lead sponsor:** gicare Pharma Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-07
- **Primary completion:** 2014-03
- **Final completion:** 2014-03
- **Target enrollment:** 308 (ACTUAL)
- **Last updated:** 2019-05-08

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01926444

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01926444, "A Phase 2a, Proof-of-Concept Study of GIC-1001 in the Management of Visceral Pain During Sedation-Free, Full Colonoscopy". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT01926444. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*